Log in

Innoviva Stock Forecast, Price & News

-0.15 (-1.42 %)
(As of 12/2/2020 12:00 AM ET)
Today's Range
Now: $10.45
50-Day Range
MA: $10.49
52-Week Range
Now: $10.45
Volume459,653 shs
Average Volume767,457 shs
Market Capitalization$1.06 billion
P/E Ratio5.33
Dividend YieldN/A
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX



Sales & Book Value

Annual Sales$261.02 million
Cash Flow$1.72 per share
Book Value$5.28 per share


Net Income$157.29 million


Market Cap$1.06 billion
Next Earnings Date2/3/2021 (Estimated)
-0.15 (-1.42 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Innoviva (NASDAQ:INVA) Frequently Asked Questions

How has Innoviva's stock been impacted by Coronavirus (COVID-19)?

Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INVA shares have decreased by 13.2% and is now trading at $10.4450.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Innoviva?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell."
View analyst ratings for Innoviva
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Innoviva?

Wall Street analysts have given Innoviva a "Sell" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Innoviva wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Innoviva's next earnings date?

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Innoviva

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, October, 28th. The biotechnology company reported $0.26 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.42 by $0.16. The biotechnology company earned $88.69 million during the quarter. Innoviva had a return on equity of 53.99% and a net margin of 67.16%.
View Innoviva's earnings history

What price target have analysts set for INVA?

1 analysts have issued 12-month price targets for Innoviva's shares. Their forecasts range from $10.00 to $10.00. On average, they expect Innoviva's share price to reach $10.00 in the next year. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for Innoviva

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Innoviva's key executives?

Innoviva's management team includes the following people:
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 51, Pay $426.92k)
  • Mr. Pavel Raifeld C.F.A., Chief Exec. Officer

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.87%), LSV Asset Management (3.62%), State Street Corp (2.12%), Arrowstreet Capital Limited Partnership (1.54%), Robeco Institutional Asset Management B.V. (0.54%) and Principal Financial Group Inc. (0.53%). Company insiders that own Innoviva stock include Geoffrey Hulme, George Bickerstaff, Innoviva, Inc and Marianne Zhen.
View institutional ownership trends for Innoviva

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Acadian Asset Management LLC, JPMorgan Chase & Co., WINTON GROUP Ltd, Alberta Investment Management Corp, AQR Capital Management LLC, and James Investment Research Inc..
View insider buying and selling activity for Innoviva

Which institutional investors are buying Innoviva stock?

INVA stock was acquired by a variety of institutional investors in the last quarter, including Voloridge Investment Management LLC, Cubist Systematic Strategies LLC, Denali Advisors LLC, Robeco Institutional Asset Management B.V., O Shaughnessy Asset Management LLC, Jackson Creek Investment Advisors LLC, Wells Fargo & Company MN, and Squarepoint Ops LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme, George Bickerstaff, and Innoviva, Inc.
View insider buying and selling activity for Innoviva

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $10.45.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.06 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 5 workers across the globe.

What is Innoviva's official website?

The official website for Innoviva is www.inva.com.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.